Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ted Clark
Tetragenetics, Inc., Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Tetragenetics, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Professor Ted Clark is the founder, Chief Scientifc Officer and a board member of Tetragenetics. He receives no cash compensation from Tetragenetics but has (b)(4) equity interest in the company. Professor Clark is also the academic director of the Tetrahymena Stock Center, an NIH funded center at Cornell.. Tetragenetics has received a new SBIR Phase II award from the NIH, with Cornell as a subcontractor and Professor Clark as the Cornell PI.
Expanding the use of Tetrahymena as a protein expression platform
The proposed project seeks to put a new and powerful technology for the production of genetically engineered proteins into the hands of basic scientists in academic and government laboratories through the establishment of a public private partnership between Tetragenetics Inc, an early stage biotechnology company in Cambridge, MA, and the NIH-funded Tetrahymena Stock Center at Cornell University in Ithaca, NY. The underlying technology platform will permit in-depth studies on proteins that were previously inaccessible with the long- term goal of developing new and improved drugs for diseases ranging from neuropathic pain to cancer and autoimmunity.
Filed on August 12, 2016.
Tell us what you know about Ted Clark's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.